Is PT-141 Legal? FDA Status and Regulations Explained (2026)

# Is PT-141 Legal? FDA Status and Regulations Explained (2026)

**Key Takeaways**

- PT-141 (bremelanotide) is **FDA-approved** — sold under the brand name Vyleesi — specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women.<sup>[1]</sup>
- Because an FDA-approved version exists, the legal pathway for PT-141 is more defined than for most peptides — but that doesn't mean every product labeled "PT-141" on the market is legal.
- Compounding pharmacies face significant restrictions when an FDA-approved equivalent exists; compounding PT-141 is only permissible under specific, narrow conditions.
- Buying PT-141 from unregulated online vendors, gray-market research chemical suppliers, or overseas pharmacies without a prescription is illegal under federal law, regardless of how those sites market their products.
- The FDA has taken enforcement action against companies marketing unapproved bremelanotide products. Consult FDA.gov for current enforcement activity.
- If you're a patient, the cleanest legal path is a prescription for brand-name Vyleesi from a licensed provider — or a compounded version from a 503A pharmacy, with the caveats explained below.

---

## Regulatory Status at a Glance

| Category | Status | Detail |
|---|---|---|
| **FDA Approval** | ✅ Approved | Bremelanotide (Vyleesi) approved August 2019 for HSDD in premenopausal women |
| **Approval Pathway** | NDA | Approved via standard NDA process; ANDA generics not yet available as of March 2026 |
| **Compounding (503A)** | Restricted | Compounding is legally complex when an FDA-approved equivalent exists; not categorically prohibited but subject to conditions |
| **Compounding (503B)** | Not on NOMS list | Not included on FDA's 503B outsourcing facility nominated list for bulk compounding |
| **DEA Scheduling** | Not Scheduled | PT-141/bremelanotide is not a DEA-controlled substance |
| **Prescription Requirement** | Prescription Only | Requires a valid prescription from a licensed provider; not available OTC |
| **Research Use (RUO)** | Not a Legal Loophole | "Research use only" labeling does not permit human use; selling RUO products for human consumption violates federal law |
| **International Status** | Varies | Not approved in EU, UK, Canada, or Australia as of March 2026 |

---

## Current FDA Status

Here's the short answer: PT-141 is the research name for bremelanotide, and bremelanotide is **FDA-approved**. The FDA granted approval in August 2019 under the brand name **Vyleesi**, manufactured by AMAG Pharmaceuticals (later acquired by Palatin Technologies' commercial partner).<sup>[1]</sup> The approved indication is specifically **hypoactive sexual desire disorder (HSDD) in premenopausal women**.

That's a narrower approval than many people assume. Vyleesi is not approved for postmenopausal women, not approved for men, and not approved for any other sexual dysfunction indication. When providers use it outside that specific population, they're operating in legally different territory — more on that in the "What 'Off-Label' Actually Means" section below.

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist with a molecular weight of approximately 1,025 Da and a CAS number of 189691-06-3.<sup>[2]</sup> It works primarily through agonism at MC3R and MC4R receptors in the central nervous system, which is mechanistically distinct from PDE5 inhibitors like sildenafil that work peripherally.<sup>[2]</sup> The approved dosing is 1.75 mg administered as a single subcutaneous injection into the abdomen or thigh approximately 45 minutes before anticipated sexual activity, with a maximum of one dose per 24 hours and no more than one dose per 24-hour period.<sup>[1]</sup>

The FDA's approval was based on two pivotal Phase III trials — RECONNECT — which enrolled over 1,200 premenopausal women with HSDD and demonstrated statistically significant improvements in sexual desire and reductions in distress associated with low desire compared to placebo.<sup>[3]</sup> Approval came after an earlier 2016 rejection, when the FDA requested additional clinical data on cardiovascular safety, particularly around transient blood pressure changes observed during trials.<sup>[1]</sup>

What the approval does **not** cover: male sexual dysfunction, erectile dysfunction, or use as a general libido enhancer. The peptide therapy community has widely discussed PT-141 for all of these uses, and there's clinical interest in them, but none carry FDA approval as of March 2026.

---

## Compounding Status

This is where PT-141 legality gets genuinely complicated, and it's worth understanding the mechanics.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, licensed compounding pharmacies can prepare customized medications for individual patients — but there's a critical restriction: pharmacies generally **cannot compound a drug that is essentially a copy of an FDA-approved commercially available product**.<sup>[4]</sup> Since Vyleesi (bremelanotide 1.75 mg/0.4 mL for subcutaneous injection) is commercially available, a 503A pharmacy compounding bremelanotide in the same strength and route of administration faces significant legal exposure.

There are narrow exceptions. A 503A pharmacy *may* be able to compound bremelanotide if:

1. A prescribing provider documents a **specific patient need** that the commercial product cannot meet — for example, a patient with a documented allergy to an excipient in Vyleesi that isn't present in the compounded formulation.
2. The compounded preparation differs meaningfully from the commercial product in a clinically relevant way (different dosing strength, different delivery mechanism, etc.).
3. The commercial product is on the FDA's drug shortage list — but Vyleesi has not been listed as in shortage as of March 2026.

For **503B outsourcing facilities**, which compound in bulk without patient-specific prescriptions, the restrictions are even tighter. Bremelanotide is not on the FDA's list of bulk drug substances that 503B facilities may use, which means bulk compounding of PT-141 by 503B facilities is not authorized under current FDA guidance.<sup>[4]</sup>

The practical reality: you'll find compounding pharmacies offering PT-141 in the peptide therapy market. Some operate in good faith under the narrow 503A exceptions described above. Others are operating in a gray area. If you're a patient, ask your provider and pharmacy specifically which exception they're relying on — a legitimate pharmacy will have a clear answer.

---

## Enforcement Actions

Because bremelanotide is FDA-approved, the FDA has a clear enforcement basis against companies selling unapproved versions. The agency has taken enforcement action against companies marketing unapproved PT-141 products — including online vendors selling injectable bremelanotide without prescriptions, gray-market "research chemical" suppliers, and overseas pharmacies shipping to US customers.<sup>[1]</sup>

The FDA's enforcement toolkit here includes Warning Letters, Import Alerts, and referrals to the Department of Justice. The FTC has also acted against companies making unsubstantiated health claims about sexual function products. If you encounter a vendor selling "PT-141" without requiring a prescription, that's not a convenience — it's a federal violation, and the vendor is taking on significant legal risk.

Patients are generally not the primary target of FDA enforcement in these cases. The agency's focus is on manufacturers, distributors, and sellers. That said, importing unapproved drug products for personal use — even in small quantities — violates federal law and can result in seizure of the shipment by US Customs and Border Protection.

For the most current enforcement activity, including any Warning Letters issued after this article's publication date, consult [FDA.gov's Warning Letters database](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters) directly.

---

## Prescription vs. Over-the-Counter vs. Research Use

**Prescription:** This is the only fully legal pathway for patients in the US. Vyleesi requires a valid prescription from a licensed healthcare provider. Your provider writes the prescription, you fill it at a licensed pharmacy, and you use it as directed. That's the legal framework, full stop.

**Over-the-counter:** There is no OTC pathway for PT-141/bremelanotide. Any product marketed as PT-141 without a prescription requirement is being sold illegally.

**"Research Use Only" (RUO):** This label gets misused constantly in the peptide market, and it's worth being direct about what it actually means. RUO products are intended for laboratory research — cell cultures, animal studies, analytical chemistry. The label is a regulatory designation that permits sale of a chemical compound without drug approval, specifically because it's **not intended for human use**. Selling an RUO product with the understanding that a buyer will inject it is a federal violation, regardless of what the label says.<sup>[4]</sup> Vendors who sell RUO PT-141 and wink at the "for research purposes only" disclaimer are not operating in a legal gray area — they're operating in a clearly illegal one.

**Gray market products:** These are products sold without a prescription, often through domestic websites or overseas pharmacies, that contain (or claim to contain) bremelanotide. Legal risks for buyers include receiving counterfeit, mislabeled, or contaminated products with no quality assurance. Legal risks for sellers include FDA enforcement, DOJ prosecution, and FTC action. There's no consumer protection if something goes wrong with a gray market product.

**International purchasing:** Ordering PT-141 from overseas pharmacies and shipping it to a US address is illegal under federal law, even for personal use. US Customs and Border Protection can and does seize such shipments. The package may be confiscated without compensation, and in some cases buyers receive a letter from CBP explaining the seizure.

---

## What "Off-Label" Actually Means

This distinction matters, and most patients — and some providers — get it wrong.

"Off-label prescribing" refers to using an **FDA-approved drug** for an indication, population, or dosage that isn't in its approved labeling. It's legal, common (roughly 20% of all prescriptions in the US are off-label), and often well-supported by evidence.<sup>[4]</sup> Physicians have broad discretion to prescribe FDA-approved drugs off-label based on their clinical judgment.

Here's the critical point: off-label prescribing only applies to **FDA-approved drugs**. PT-141/bremelanotide *is* FDA-approved — but only for HSDD in premenopausal women. So:

- A provider prescribing Vyleesi (brand-name bremelanotide) to a **postmenopausal woman** for HSDD is prescribing off-label. That's legally permissible, though the provider takes on additional liability for using it outside the approved population.
- A provider prescribing Vyleesi to a **man** for sexual dysfunction is prescribing off-label. Again, legally permissible, but with liability implications.
- A provider prescribing **compounded bremelanotide** that doesn't meet the narrow 503A exceptions is in a different, more complicated legal position — because the issue isn't just off-label use, it's whether the compounded product itself is legally prepared.

From a malpractice standpoint, off-label prescribing of an approved drug is defensible when there's a documented clinical rationale and informed patient consent. Prescribing a compounded version when the commercial product is available, without documented clinical justification, is harder to defend if something goes wrong.

If you're a patient being offered PT-141 by a provider, ask specifically: "Are you prescribing brand-name Vyleesi, or a compounded version? If compounded, what's the clinical justification for not using the commercial product?" A good provider will have a clear answer.

---

## State-Level Variations

Federal law sets the floor, but states add layers. A few areas where state law matters for PT-141 legality:

**State pharmacy board oversight:** State pharmacy boards regulate compounding pharmacies licensed in their state. Some boards have issued specific guidance on peptide compounding; others haven't addressed it explicitly. A 503A pharmacy in one state may interpret the "essentially a copy" restriction differently than one in another state. This isn't a loophole — it's a regulatory gap that the FDA is progressively closing.

**Telemedicine prescribing:** Most states now permit telemedicine prescribing for non-controlled substances like bremelanotide, but requirements vary. Some states require an in-person visit before prescribing certain medications. If you're getting PT-141 through a telehealth platform, your provider should be licensed in your state and should document a proper evaluation — not just a checkbox questionnaire.

**State consumer protection:** Several states have active consumer protection enforcement against companies selling unregulated peptide products. California, New York, and Florida have historically been active in this space, though specific enforcement actions against PT-141 vendors are not confirmed in our current data.

If you're working with a clinic, verify that the prescribing provider is licensed in your state and that the compounding pharmacy is licensed in either your state or the pharmacy's home state. The [MyPeptideMatch clinic finder](/clinics) can help you identify vetted providers operating in your area.

---

## International Status

PT-141's legal status outside the US is notably different, and more restrictive.

**European Union / EMA:** Bremelanotide has not received marketing authorization from the European Medicines Agency as of March 2026. It is not approved for any indication in EU member states, meaning it cannot be legally prescribed or dispensed through normal pharmacy channels in Europe.

**United Kingdom / MHRA:** The UK Medicines and Healthcare products Regulatory Agency has not approved bremelanotide. Post-Brexit, the UK operates its own approval process, and no application has received authorization as of March 2026.

**Canada / Health Canada:** Health Canada has not approved bremelanotide. It is not available through licensed Canadian pharmacies, and importing it for personal use is not permitted under Canadian federal drug law.

**Australia / TGA:** The Therapeutic Goods Administration has not approved bremelanotide, and it is not listed on the Australian Register of Therapeutic Goods. Importation for personal use without TGA authorization is prohibited.

The practical implication: if you're traveling internationally or considering purchasing PT-141 from an overseas source, you're dealing with a product that lacks regulatory oversight in most of the world outside the US. Quality, purity, and dosing accuracy are unverified.

---

## What This Means for Patients

If you're trying to figure out whether you can legally access PT-141, here's what to actually look for:

**Verify the clinic is operating legally.** A legitimate provider will prescribe brand-name Vyleesi or, if compounding, will have a documented clinical reason why the commercial product doesn't meet your specific needs. They'll use a licensed 503A pharmacy. They'll require a proper medical evaluation, not just an online form. Our [clinic finder](/clinics) lists vetted peptide therapy providers.

**Red flags that suggest illegal activity:**
- No prescription required
- Prices dramatically lower than Vyleesi's retail cost (~$800-$1,000 per dose without insurance)
- Product labeled "research use only" but marketed for human use
- Shipped from overseas without a US pharmacy label
- No provider consultation required

**Questions to ask your provider:**
- "Are you prescribing brand-name Vyleesi or a compounded version?"
- "If compounded, which 503A pharmacy are you using, and what's the clinical justification?"
- "Is the pharmacy accredited by PCAB (Pharmacy Compounding Accreditation Board)?"
- "Are you licensed to practice in my state?"

**If you're offered an illegal product:** Don't purchase it. The risks aren't just legal — unregulated injectable products carry serious contamination and dosing risks. Report suspicious sellers to the FDA's MedWatch program at [fda.gov/safety/medwatch](https://www.fda.gov/safety/medwatch) or through the FDA's online reporting portal.

---

## Legal Alternatives

If accessing Vyleesi isn't feasible — whether due to cost, insurance coverage, or eligibility — there are other legally available options worth knowing about.

**FDA-approved options for sexual dysfunction:**
- **Addyi (flibanserin):** FDA-approved for HSDD in premenopausal women, taken as a daily oral tablet. Different mechanism (serotonin/dopamine modulation rather than melanocortin agonism). Approved in 2015.<sup>[1]</sup>
- **PDE5 inhibitors (sildenafil, tadalafil):** FDA-approved for erectile dysfunction in men. Off-label use in women has been studied but is not approved.

**Other peptides in the sexual wellness space:** The [PT-141 peptide profile](/peptides/pt-141) on MyPeptideMatch covers the clinical evidence in detail. For related peptides with different regulatory profiles, see our guides on [kisspeptin](/peptides/kisspeptin) and the broader [sexual wellness peptide category](/categories/sexual-wellness).

**Non-peptide considerations:** For women with HSDD, evidence-based non-pharmacological approaches — including sex therapy, couples counseling, and treatment of underlying hormonal imbalances — are often recommended as first-line or adjunctive treatment. These don't require navigating peptide regulations at all.

---

## What the Evidence Does Not Show

**Pending FDA decisions:** There are no publicly confirmed pending NDA supplements for bremelanotide that would expand its approved indication to men or postmenopausal women as of March 2026. Palatin Technologies has conducted research in these populations, but no approval is imminent based on publicly available information.

**Compounding regulatory clarity:** The FDA has not issued a final rule specifically addressing bremelanotide compounding in the context of the 503A "essentially a copy" restriction. The regulatory position described in this article reflects current FDA guidance and legal interpretation, but a formal agency ruling could change the picture.

**Long-term safety data:** The RECONNECT trials that supported Vyleesi's approval had a 52-week duration.<sup>[3]</sup> Long-term safety data beyond one year — particularly for off-label populations — is limited. The transient blood pressure elevation observed in trials (mean increase of approximately 6 mmHg systolic, lasting 12 hours) has cardiovascular implications that haven't been fully characterized in longer-term use.<sup>[1]</sup>

**Male use evidence base:** The clinical literature on PT-141 for male sexual dysfunction includes earlier Phase II studies showing improvements in erectile function, but these did not result in an NDA submission for male indications.<sup>[2]</sup> The evidence base for male use exists but is not at the level required for FDA approval.

**State-level regulatory evolution:** Several states are actively reviewing their peptide compounding regulations. The legal landscape at the state level is more fluid than at the federal level, and guidance that's current as of March 2026 may shift.

---

## FAQ

### Is PT-141 legal in the US?

Yes — with specifics. Bremelanotide (the drug PT-141 refers to) is FDA-approved as Vyleesi for HSDD in premenopausal women. With a valid prescription from a licensed provider, you can legally obtain and use it. What's illegal: buying it without a prescription, purchasing it from unregulated online vendors, ordering it from overseas, or obtaining it labeled as "research use only" for human injection.

### Can my doctor prescribe PT-141?

Yes. Any licensed US physician can prescribe Vyleesi (bremelanotide) for its approved indication — HSDD in premenopausal women — or off-label for other populations based on clinical judgment. The prescription must be filled at a licensed pharmacy. If your provider is prescribing a compounded version, ask them to explain why the commercial product isn't appropriate for your situation.

### Is it legal to buy PT-141 online?

Only through a licensed online pharmacy with a valid prescription. Buying from gray-market websites, research chemical vendors, or overseas pharmacies without a prescription is illegal under federal law. The fact that many such sites operate openly doesn't make them legal — it means enforcement hasn't caught up with them yet.

### What happens if I'm caught with PT-141?

If you have a valid prescription and a product dispensed by a licensed pharmacy, there's no legal issue. If you're found with PT-141 purchased illegally — from an overseas source, without a prescription, or labeled as RUO — the product can be seized. Patients are rarely prosecuted for personal-use quantities, but there's no guarantee, and you'd have no legal recourse if the product was contaminated or caused harm.

### Is PT-141 a controlled substance?

No. Bremelanotide is not scheduled by the DEA and is not a controlled substance under the Controlled Substances Act. This is one reason it's available through telemedicine platforms in states that permit telehealth prescribing for non-controlled medications.

### Can compounding pharmacies make PT-141?

In limited circumstances. Because an FDA-approved commercial product (Vyleesi) exists, 503A compounding pharmacies cannot simply compound bremelanotide as a routine alternative. They need a documented clinical reason — typically a patient-specific need that the commercial product can't meet, such as an excipient allergy. 503B outsourcing facilities cannot bulk compound bremelanotide under current FDA guidance. Ask any pharmacy offering compounded PT-141 to explain specifically which exception they're operating under.

### Is "research use only" PT-141 legal?

Not for human use. RUO designation means a product is intended for laboratory research, not for injection into people. Vendors who sell RUO PT-141 with a wink are violating federal law. Buyers who inject RUO products are using an unregulated substance with no quality oversight — and have no legal protection if something goes wrong.

### Has anyone been prosecuted for PT-141?

The FDA has taken enforcement action against companies marketing unapproved bremelanotide products, and the DOJ has pursued cases involving illegal peptide distribution more broadly. Individual patient prosecutions for personal-use quantities are rare, but vendors, distributors, and providers operating outside the law face significant legal exposure. Consult [FDA.gov](https://www.fda.gov) for confirmed, current enforcement activity.

### Where can I find a legitimate PT-141 provider?

The [MyPeptideMatch clinic finder](/clinics) lists vetted peptide therapy clinics across the US. Look for providers who require a full medical consultation, use licensed compounding pharmacies or prescribe brand-name Vyleesi, and are transparent about their prescribing rationale. The [PT-141 peptide profile](/peptides/pt-141) on this site also covers clinical evidence and dosing in detail.

---

## References

1. U.S. Food and Drug Administration. "FDA approves new treatment for hypoactive sexual desire disorder in premenopausal women." FDA News Release. August 21, 2019. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-hypoactive-sexual-desire-disorder-premenopausal-women
2. Kingsberg SA, et al. "Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials." *Obstetrics & Gynecology*. 2019;134(5):899-908. PMID: 31599840
3. Simon JA, et al. "Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder." *Obstetrics & Gynecology*. 2019;134(5):909-917. PMID: 31599839
4. U.S. Food and Drug Administration. "Compounding and the FDA: Questions and Answers." FDA Guidance. Available at: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers

---

*Legal status last verified: March 2026. Regulatory status can change. Consult FDA.gov and a licensed healthcare provider for the most current information.*

*This content is for informational purposes only and does not constitute medical advice, legal advice, or a recommendation to use any specific product or treatment. Consult a licensed healthcare provider before starting any treatment. PT-141/bremelanotide is a prescription medication; access outside of a valid prescription is illegal under federal law.*